Oruka officer plans $463K stock sale via options

Oruka Therapeutics, Inc. (ORKA) has a notice of proposed sale of securities filed under Rule 144 by officer Laura Sandler.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) has a notice of proposed sale of securities filed under Rule 144 by officer Laura Sandler. The notice covers the planned resale of 5,000 shares of common stock on or after 09/01/2026 on NASDAQ, to be delivered through exercise of stock options for cash. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker.

The filing also lists prior sales of Oruka common stock for Sandler during the past three months, including 5,000 shares sold on 07/01/2026 and 600 shares sold on 06/15/2026.

Key Figures

Shares of common stock to be sold: 5,000 shares Approximate value of shares to be sold: $463,100.00 Shares sold on 07/01/2026: 5,000 shares +3 more

6 metrics

Shares of common stock to be sold 5,000 shares Planned Rule 144 sale on or after 09/01/2026

Approximate value of shares to be sold $463,100.00 Value listed for 5,000 common shares associated with 09/01/2026 entry

Shares sold on 07/01/2026 5,000 shares Past three months sales section for Laura Sandler

Proceeds from 07/01/2026 sale $472,078.50 Sale of 5,000 common shares on 07/01/2026

Shares sold on 06/15/2026 600 shares Past three months sales section for Laura Sandler

Proceeds from 06/15/2026 sale $41,814.00 Sale of 600 common shares on 06/15/2026

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options, Form 144

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for LAURA SANDLER 855 Oak Grove Avenue Suite 100"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/01/2026 | Exercise of Stock Options | Issuer"

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ORKA?

It discloses that officer Laura Sandler has filed a Rule 144 notice to sell up to 5,000 shares of Oruka Therapeutics, Inc. common stock, to be issued from an exercise of stock options for cash and sold on or after 09/01/2026 on NASDAQ.

How many ORKA shares are planned to be sold under this Form 144?

The notice covers a proposed sale of 5,000 shares of Oruka Therapeutics, Inc. common stock, to be delivered through the exercise of stock options and sold on or after 09/01/2026.

What is the approximate value of the ORKA shares covered by the planned sale?

The Form 144 lists an approximate value of $463,100.00 for the 5,000 shares of Oruka Therapeutics, Inc. common stock covered by the planned Rule 144 sale as of the 09/01/2026 entry.

Which broker is handling the proposed ORKA share sale?

The proposed sale of 5,000 ORKA common shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

What ORKA share sales has Laura Sandler made in the past three months?

The filing reports that Laura Sandler sold 5,000 ORKA common shares on 07/01/2026 for $472,078.50 and 600 shares on 06/15/2026 for $41,814.00 under the three‑month sales history section.

Is the ORKA Form 144 sale related to stock options?

Yes. The securities to be sold are described as common stock to be issued upon exercise of stock options for cash, with the issuer listed as Oruka Therapeutics, Inc. and a planned sale date of 09/01/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:50 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:50 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002075401
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Oruka Therapeutics, Inc.
SEC File Number	000-22873
Address of Issuer	855 Oak Grove Avenue Suite 100 Menlo Park CALIFORNIA 94025
Phone	6506067910
Name of Person for Whose Account the Securities are To Be Sold	LAURA SANDLER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5000	463100.00	66209699	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2026	Exercise of Stock Options	Issuer			5000	09/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for LAURA SANDLER 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	07/01/2026	5000	472078.50
LAURA SANDLER 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	06/15/2026	600	41814.00

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Laura Sandler
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)